{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T10:00:26Z","timestamp":1790330426233,"version":"4.1.0"},"reference-count":40,"publisher":"The Endocrine Society","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"abstract":"Abstract<\/jats:title>\n \n Context:<\/jats:title>\n Lorcaserin is a novel selective agonist of the serotonin 2C receptor.<\/jats:p>\n <\/jats:sec>\n \n Objective:<\/jats:title>\n Our objective was to evaluate the effects of lorcaserin on body weight, cardiovascular risk factors, and safety in obese and overweight patients.<\/jats:p>\n <\/jats:sec>\n \n Design and Setting:<\/jats:title>\n This randomized, placebo-controlled, double-blind, parallel arm trial took place at 97 U.S. research centers.<\/jats:p>\n <\/jats:sec>\n \n Patients:<\/jats:title>\n Patients included 4008 patients, aged 18\u201365 yr, with a body mass index between 30 and 45 kg\/m2 or between 27 and 29.9 kg\/m2 with an obesity-related comorbid condition.<\/jats:p>\n <\/jats:sec>\n \n Interventions:<\/jats:title>\n Patients were randomly assigned in a 2:1:2 ratio to receive lorcaserin 10 mg twice daily (BID), lorcaserin 10 mg once daily (QD), or placebo. All patients received diet and exercise counseling.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome Measures:<\/jats:title>\n The ordered primary endpoints were proportion of patients achieving at least 5% reduction in body weight, mean change in body weight, and proportion of patients achieving at least 10% reduction in body weight at 1 yr. Serial echocardiograms monitored heart valve function.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Significantly more patients treated with lorcaserin 10 mg BID and QD lost at least 5% of baseline body weight (47.2 and 40.2%, respectively) as compared with placebo (25.0%, P &lt; 0.001 vs. lorcaserin BID). Least squares mean (95% confidence interval) weight loss with lorcaserin BID and QD was 5.8% (5.5\u20136.2%) and 4.7% (4.3\u20135.2%), respectively, compared with 2.8% (2.5\u20133.2%) with placebo (P &lt; 0.001 vs. lorcaserin BID; least squares mean difference, 3.0%). Weight loss of at least 10% was achieved by 22.6 and 17.4% of patients receiving lorcaserin 10 mg BID and QD, respectively, and 9.7% of patients in the placebo group (P &lt; 0.001 vs. lorcaserin BID). Headache, nausea, and dizziness were the most common lorcaserin-related adverse events. U.S. Food and Drug Administration-defined echocardiographic valvulopathy occurred in 2.0% of patients on placebo and 2.0% on lorcaserin 10 mg BID.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Lorcaserin administered in conjunction with a lifestyle modification program was associated with dose-dependent weight loss that was significantly greater than with placebo.<\/jats:p>\n <\/jats:sec>","DOI":"10.1210\/jc.2011-1256","type":"journal-article","created":{"date-parts":[[2011,7,27]],"date-time":"2011-07-27T23:56:10Z","timestamp":1311810970000},"page":"3067-3077","source":"Crossref","is-referenced-by-count":454,"title":["A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial"],"prefix":"10.1210","volume":"96","author":[{"given":"Meredith C.","family":"Fidler","sequence":"first","affiliation":[{"name":"Arena Pharmaceuticals (M.C.F., M.S., B.R., W.R.S., C.M.A.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matilde","family":"Sanchez","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals (M.C.F., M.S., B.R., W.R.S., C.M.A.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Raether","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals (M.C.F., M.S., B.R., W.R.S., C.M.A.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J.","family":"Weissman","sequence":"additional","affiliation":[{"name":"MedStar Health Research Institute at Washington Hospital Center and Georgetown University (N.J.W.), Washington, D.C. 20010"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven R.","family":"Smith","sequence":"additional","affiliation":[{"name":"and Translational Research Institute for Metabolism and Diabetes (S.R.S.), Florida Hospital and the Sanford-Burnham Medical Research Institute, Orlando, Florida 32789"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Shanahan","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals (M.C.F., M.S., B.R., W.R.S., C.M.A.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christen M.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Arena Pharmaceuticals (M.C.F., M.S., B.R., W.R.S., C.M.A.), San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071616062322300_B1","article-title":"Fact sheet: obesity and overweight. Report no. 311","author":"World Health Organization","year":"2006"},{"key":"2020071616062322300_B2","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1161\/01.CIR.0000140086.88453.9A","article-title":"Prevention Conference VII: obesity, a worldwide epidemic related to heart disease and stroke: executive summary.","volume":"110","author":"Eckel","year":"2004","journal-title":"Circulation"},{"key":"2020071616062322300_B3","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1001\/jama.282.16.1523","article-title":"The disease burden associated with overweight and obesity.","volume":"282","author":"Must","year":"1999","journal-title":"JAMA"},{"key":"2020071616062322300_B4","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.106.171016","article-title":"Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism.","volume":"113","author":"Poirier","year":"2006","journal-title":"Circulation"},{"key":"2020071616062322300_B5","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.ijo.0802204","article-title":"Prospective association between obesity and depression: evidence from the Alameda County Study.","volume":"27","author":"Roberts","year":"2003","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2020071616062322300_B6","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/ard.2006.065904","article-title":"Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis.","volume":"66","author":"Christensen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2020071616062322300_B7","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1464-5491.2005.01615.x","article-title":"Long-term influences of body-weight changes, independent of the attained weight, on risk of impaired glucose tolerance and type 2 diabetes.","volume":"22","author":"Black","year":"2005","journal-title":"Diabet Med"},{"key":"2020071616062322300_B8","first-page":"397","article-title":"Beneficial health effects of modest weight loss.","volume":"16","author":"Goldstein","year":"1992","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2020071616062322300_B9","first-page":"51S","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report. National Institutes of Health.","volume":"6","year":"1998","journal-title":"Obes Res"},{"key":"2020071616062322300_B10","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1210\/en.2007-1321","article-title":"Serotonin 5-HT2C receptor agonist promotes hypophagia via downstream activation of melanocortin 4 receptors.","volume":"149","author":"Lam","year":"2008","journal-title":"Endocrinology"},{"key":"2020071616062322300_B11","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJM199809103391103","article-title":"An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group.","volume":"339","author":"Weissman","year":"1998","journal-title":"N Engl J Med"},{"key":"2020071616062322300_B12","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1021\/jm0709034","article-title":"Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity.","volume":"51","author":"Smith","year":"2008","journal-title":"J Med Chem"},{"key":"2020071616062322300_B13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1124\/jpet.107.133348","article-title":"Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization.","volume":"325","author":"Thomsen","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071616062322300_B14","first-page":"A80","article-title":"APD356, an orally active selective 5HT2C agonist, reduces body weight in obese adult men and women.","volume":"55","author":"Smith","year":"2006","journal-title":"Diabetes"},{"key":"2020071616062322300_B15","first-page":"A1","article-title":"Effect of APD356, a selective 5-HT2C agonist, on weight loss in a 4-week study of healthy obese patients","volume":"13","author":"Smith","journal-title":"Obes Res"},{"key":"2020071616062322300_B16","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/oby.2008.537","article-title":"Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.","volume":"17","author":"Smith","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"2020071616062322300_B17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management.","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"key":"2020071616062322300_B18","first-page":"1061","article-title":"Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997.","volume":"46","author":"Centers for Disease Control and Prevention (CDC)","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2020071616062322300_B19","article-title":"Energy and protein requirements. Report of a joint FAO\/WHO\/ONU expert consultation. Tech Rep Ser 724","author":"World Health Organization","year":"1985"},{"key":"2020071616062322300_B20","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1023\/A:1015081805439","article-title":"Psychometric evaluation of the impact of weight on quality of life-lite questionnaire (IWQOL-lite) in a community sample.","volume":"11","author":"Kolotkin","year":"2002","journal-title":"Qual Life Res"},{"key":"2020071616062322300_B21","article-title":"Beck Depression Inventory-II","author":"Beck","year":"1996"},{"key":"2020071616062322300_B22","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0894-7317(03)00335-3","article-title":"Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography.","volume":"16","author":"Zoghbi","year":"2003","journal-title":"J Am Soc Echocardiogr"},{"key":"2020071616062322300_B23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0894-7317(05)80358-X","article-title":"Use of multiple views in the echocardiographic assessment of pulmonary artery systolic pressure.","volume":"8","author":"Abramson","year":"1995","journal-title":"J Am Soc Echocardiogr"},{"key":"2020071616062322300_B24","first-page":"283","article-title":"Measurement of intracardiac pressures. State of the art\u20131986.","volume":"11","author":"Nishimura","year":"1986","journal-title":"Herz"},{"key":"2020071616062322300_B25","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1093\/biomet\/75.4.800","article-title":"A sharper Bonferroni procedure for multiple tests of significance.","volume":"75","author":"Hochberg","year":"1988","journal-title":"Biometrika"},{"key":"2020071616062322300_B26","first-page":"A482","article-title":"Lorcaserin, a selective 5-HT2C agonist, is efficacious for weight loss across patient subgroups.","volume":"59","author":"Anderson","year":"2010","journal-title":"Diabetes"},{"key":"2020071616062322300_B27","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S0028-3908(99)00010-6","article-title":"A review of central 5-HT receptors and their function.","volume":"38","author":"Barnes","year":"1999","journal-title":"Neuropharmacology"},{"key":"2020071616062322300_B28","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s002130000504","article-title":"Similarities in the action of Ro 60\u20130175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat.","volume":"152","author":"Clifton","year":"2000","journal-title":"Psychopharmacology (Berl)"},{"key":"2020071616062322300_B29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0022-3565(24)37669-4","article-title":"5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential.","volume":"286","author":"Martin","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"2020071616062322300_B30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002130050407","article-title":"5-HT2C receptor activation decreases appetite and body weight in obese subjects.","volume":"133","author":"Sargent","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"2020071616062322300_B31","first-page":"S51","article-title":"Hypothalamic serotonin: pharmacological, biochemical, and behavioral analyses of its feeding-suppressive action.","volume":"11","author":"Leibowitz","year":"1988","journal-title":"Clin Neuropharmacol"},{"key":"2020071616062322300_B32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jc.2010-1848","article-title":"Lorcaserin, A 5-HT2C receptor agonist, reduces body weight by decreasing energy intake without influencing energy expenditure.","volume":"96","author":"Martin","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616062322300_B33","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/sj.ejcn.1601375","article-title":"Lipoprotein responses to weight loss and weight maintenance in high-risk obese subjects.","volume":"56","author":"Ditschuneit","year":"2002","journal-title":"Eur J Clin Nutr"},{"key":"2020071616062322300_B34","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1001\/archinte.160.12.1797","article-title":"Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: results from the Swedish Obese Subjects study.","volume":"160","author":"Karason","year":"2000","journal-title":"Arch Intern Med"},{"key":"2020071616062322300_B35","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/oby.2000.32","article-title":"Overweight, obesity, and blood pressure: the effects of modest weight reduction.","volume":"8","author":"Mertens","year":"2000","journal-title":"Obes Res"},{"key":"2020071616062322300_B36","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"2020071616062322300_B37","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/oby.2001.13","article-title":"Development of a brief measure to assess quality of life in obesity.","volume":"9","author":"Kolotkin","year":"2001","journal-title":"Obes Res"},{"key":"2020071616062322300_B38","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"August 28 Valvular heart disease associated with fenfluramine-phentermine.","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"2020071616062322300_B39","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1056\/NEJMp068265","article-title":"Drugs and valvular heart disease.","volume":"356","author":"Roth","year":"2007","journal-title":"N Engl J Med"},{"key":"2020071616062322300_B40","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.brat.2009.05.004","article-title":"August. Predictors of attrition and weight loss success: results from a randomized controlled trial.","volume":"47","author":"Fabricatore","year":"2009","journal-title":"Behav Res Ther"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/10\/3067\/9110404\/jcem3067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/96\/10\/3067\/9110404\/jcem3067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T16:02:20Z","timestamp":1741363340000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/96\/10\/3067\/2834879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":40,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2011-1256","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13343956.14713054","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.13343956.14846064","asserted-by":"object"}]},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,1]]}}}